Secondary resistance to the PI3K inhibitor copanlisib in marginal zone lymphoma

被引：0
|
作者：
Arribas, A. [1 ]
Napoli, S. [1 ]
Cascione, L. [1 ]
Gaudio, E. [1 ]
Bordone-Pittau, R. [2 ]
Barreca, M. [3 ]
Sartori, G. [1 ]
Chiara, T. [1 ]
Spriano, F. [1 ]
Rinaldi, A. [1 ]
Stathis, A. [4 ]
Stussi, G. [5 ]
Rossi, D. [4 ]
Emanuele, Z. [4 ]
Bertoni, F. [1 ]
机构：
[1] Fac Biomed Sci USI, Oncol Res Inst, Bellinzona, Switzerland
[2] Oncol Inst Southern Switzerland, Ematol Lab Ematol EOLAB, Bellinzona, Switzerland
[3] Univ Palermo, Dept Biol Chem & Pharmaceut Sci & Technol, Palermo, Italy
[4] Oncol Inst Southern Switzerland, Fac Biomed Sci USI, Bellinzona, Switzerland
[5] Oncol Inst Southern Switzerland, Ematol Unita Leucemie IOSI, Bellinzona, Switzerland
来源：
EUROPEAN JOURNAL OF CANCER | 2020年 / 138卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
149
引用
收藏
页码：S40 / S40
页数：1
相关论文
共 50 条
  • [1] Copanlisib: Novel PI3K Inhibitor for the Treatment of Lymphoma
    Kumar, Anshul
    Bhatia, Rohit
    Chawla, Pooja
    Anghore, Durgadas
    Saini, Vipin
    Rawal, Ravindra K.
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2020, 20 (10) : 1158 - 1172
  • [2] Marginal zone lymphoma: PI3Kδ inhibition and beyond
    不详
    MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY, 2022, 15 (SUPPL 2) : S25 - S26
  • [3] The ATR inhibitor elimusertib exhibits anti-lymphoma activity and synergizes with the PI3K inhibitor copanlisib
    Sartori, Giulio
    Tarantelli, Chiara
    Spriano, Filippo
    Gaudio, Eugenio
    Cascione, Luciano
    Mascia, Michele
    Barreca, Marilia
    Arribas, Alberto J.
    Licenziato, Luca
    Golino, Gaetanina
    Ferragamo, Adele
    Pileri, Stefano
    Damia, Giovanna
    Zucca, Emanuele
    Stathis, Anastasios
    Politz, Oliver
    Wengner, Antje M.
    Bertoni, Francesco
    BRITISH JOURNAL OF HAEMATOLOGY, 2024, 204 (01) : 191 - 205
  • [4] Pharmacological screening identified promising combination partners in marginal zone lymphoma models with secondary resistance to BTK and PI3K inhibitors
    Arribas, A.
    Vultaggio, S.
    Andronache, A.
    Robusto, M.
    Fancelli, D.
    Cannas, E.
    Spriano, F.
    Tarantelli, C.
    Rossi, D.
    Zucca, E.
    Stathis, A.
    Varasi, M.
    Mercurio, C.
    Bertoni, F.
    EUROPEAN JOURNAL OF CANCER, 2022, 174 : S108 - S108
  • [5] Copanlisib: An Intravenous Phosphatidylinositol 3-Kinase (PI3K) Inhibitor for the Treatment of Relapsed Follicular Lymphoma
    Eltantawy, Adel
    Vallejos, Ximena
    Sebea, Elrodia
    Evans, Kirsten
    ANNALS OF PHARMACOTHERAPY, 2019, 53 (09) : 954 - 958
  • [6] Phase 2A Study of Copanlisib, a Novel PI3K Inhibitor, in Patients with Indolent Lymphoma
    Dreyling, Martin
    Cunningham, David
    Bouabdallah, Krimo
    Assouline, Sarit
    Van den Neste, Eric
    Vitolo, Umberto
    Giurescu, Marius
    Mappa, Silvia
    Grunert, Julia
    Childs, Barrett H.
    Morschhauser, Franck
    BLOOD, 2014, 124 (21)
  • [7] Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma
    Dreyling, M.
    Morschhauser, F.
    Bouabdallah, K.
    Bron, D.
    Cunningham, D.
    Assouline, S. E.
    Verhoef, G.
    Linton, K.
    Thieblemont, C.
    Vitolo, U.
    Hiemeyer, F.
    Giurescu, M.
    Garcia-Vargas, J.
    Gorbatchevsky, I.
    Liu, L.
    Koechert, K.
    Pena, C.
    Neves, M.
    Childs, B. H.
    Zinzani, P. L.
    ANNALS OF ONCOLOGY, 2017, 28 (09) : 2169 - 2178
  • [8] Novel marginal zone lymphoma models of resistance to the dual inhibition of PI3K and BCL2
    Arribas, Alberto J.
    Cascione, Luciano
    Cannas, Eleonora
    Bellerjeau, Helen
    Fuzio, Federica
    Noguera, Aleix
    Rinaldi, Andrea
    Esteller, Manel
    Zucca, Emanuele
    Alimonti, Andrea
    Rossi, Davide
    Stathis, Anastasios
    Bertoni, Francesco
    CANCER RESEARCH, 2024, 84 (06)
  • [9] Preclinical Activity of PI3K Inhibitor Copanlisib in Gastrointestinal Stromal Tumor
    Garcia-Valverde, Alfonso
    Rosell, Jordi
    Serna, Garazi
    Valverde, Claudia
    Carles, Joan
    Nuciforo, Paolo
    Fletcher, Jonathan A.
    Arribas, Joaquin
    Politz, Oliver
    Serrano, Cesar
    MOLECULAR CANCER THERAPEUTICS, 2020, 19 (06) : 1289 - 1297
  • [10] CAR T cells in marginal zone lymphoma (MZL) models with acquired resistance to PI3K and BTK inhibitors
    Wang, S.
    Arribas, A. J.
    Tarantelli, C.
    Pradier, A.
    Zucca, E.
    Rossi, D.
    Simonetta, F.
    Bertoni, F.
    EUROPEAN JOURNAL OF CANCER, 2022, 174 : S106 - S106
12345